Bone marrow mesenchymal stem cells in the treatment of patients with knee osteoarthritis
Open Access
- 15 September 2025
- journal article
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 15 (3) , 126-133
Abstract
Background. The use of mesenchymal stem cells (MSCs) in joint lesions is an extremely controversial issue due to the presence of numerous unresolved problems both in understanding the biological properties of MSCs and in terms of their practical application. The purpose of the study was to evaluate the functional results and clinical efficacy of using autologous MSCs obtained from bone marrow in the treatment of patients with post-traumatic osteoarthritis (PTOA) of the knee joint (KS) in the early stages, during a six-month observation period. Materials and methods. 28 patients with PTOA of the knee joint of stage I–II according to Kellgren-Lawrence were treated. Among them, 11 (39.0 %) were men and 17 (61.0 %) were women, the average age was 44.80 ± 10.95 years. The average period after the injury was 7.8 ± 0.5 years. MSCs were harvested from the iliac wing and cultured in a biotechnology laboratory. Intra-articular injection was performed once during exacerbation of PTOA (50 million cells). Efficacy was assessed after 6 months. Evaluation criteria: need for NSAIDs, number of exacerbations of PTOA; functional status of the joint according to Lisholm and WOMAC. Pain syndrome was assessed using the visual analog scale (VAS), quality of life according to the 36-Item Short Form Survey (SF-36) scale. Results. After 6 months after the use of MSC, positive dynamics were obtained in all categories of assessment of the functional status of the knee joint: pain according to VAS decreased to 2.2 ± 0.3 (p < 0.05); functional activity according to the Lisholm scale increased by 29.4 % (p < 0.01), the total WOMAC index decreased by 51.7 % (p < 0.01); the quality of life index increased by 57.7 ± 9.3 % when assessed using SF-36 (p < 0.01). In addition, during the 6-month clinical observation period following the use of MSCs, a significant decrease in the frequency of exacerbations of PTOA compared to the previous 6-month period and a decrease in the need for NSAIDs were demonstrated. Conclusion. MSCs are an effective and safe method of treating PTOA of the knee in the early stages, accompanied by a significant decrease in pain syndrome indicators, improvement in joint function and quality of life, as well as a decrease in the number of PTOA exacerbations and the need for NSAIDs for at least 6 months.Keywords
This publication has 22 references indexed in Scilit:
- Post-traumatic osteoarthritis: A review of pathogenic mechanisms and novel targets for mitigationBone Reports, 2023
- Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the knee: a single-arm, open-label studyEuropean Journal of Orthopaedic Surgery & Traumatology, 2020
- Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial InflammationStem Cells Translational Medicine, 2019
- Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical TrialStem Cells Translational Medicine, 2019
- Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot studyCytotherapy, 2019
- Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II TrialStem Cells Translational Medicine, 2018
- Preliminary results of autologous adipose-derived stem cells in early knee osteoarthritis: identification of a subpopulation with greater responseInternational Orthopaedics, 2018
- Higher Pericyte Content and Secretory Activity of Microfragmented Human Adipose Tissue Compared to Enzymatically Derived Stromal Vascular FractionStem Cells Translational Medicine, 2018
- Injectable Cultured Bone Marrow–Derived Mesenchymal Stem Cells in Varus Knees With Cartilage Defects Undergoing High Tibial Osteotomy: A Prospective, Randomized Controlled Clinical Trial With 2 Years' Follow‐upArthroscopy, 2013
- Stem cell therapy in a caprine model of osteoarthritisArthritis & Rheumatism, 2003